Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer

Jisup Kim, Sinae Kim, Hye Sun Lee, Wookyeom Yang, Hanbyoul Cho, Doo Byung Chay, Seong Jin Cho, Soonwon Hong, Jae-Hoon Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Monoclonal antibodies targeting programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) demonstrated promising clinical response. The predictive/prognostic value of PD-1/PD-L1 immunohistochemistry (IHC) has been evaluated in many cancer types. However, the prognostic value of PD-1/PD-L1 IHC has not been evaluated in endometrial cancer. Methods: We conducted a retrospective study to quantify the IHC CD8, PD-1, and PD-L1 expressions in immune cells at center of tumor (CT), invasive margin (IM), and/or tumor cell in 183 primary endometrial cancer samples from a single cohort, followed by their reciprocal combinations, including compartmental differences, and correlated them with overall survival (OS) and progression-free survival (PFS). Results: In repeated Cox multivariable models adjusted by clinicoimmunopathologic factors, high CT-PD-L1 was an independent adverse prognostic factor for PFS in all patients and in the microsatellite-stable subgroup. Immune marker ratios revealed independently shorter PFS for high CT-PD-L1/CT-CD8 and CT-PD-L1/CT-PD-1 ratios. Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-L1 revealed significantly different survival among groups. Conclusions: The high PD-L1/CD8 ratio and the high expression of PD-L1 on immune cells were independent poor prognostic factors for PFS in endometrial cancer, providing insights into the tumor microenvironment.

Original languageEnglish
Pages (from-to)381-387
Number of pages7
JournalGynecologic Oncology
Volume149
Issue number2
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Programmed Cell Death 1 Receptor
Endometrial Neoplasms
Ligands
Neoplasms
Disease-Free Survival
Cell Death
Immunohistochemistry
CD274 Antigen
Tumor Microenvironment
Survival
Proportional Hazards Models
Microsatellite Repeats

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Kim, Jisup ; Kim, Sinae ; Lee, Hye Sun ; Yang, Wookyeom ; Cho, Hanbyoul ; Chay, Doo Byung ; Cho, Seong Jin ; Hong, Soonwon ; Kim, Jae-Hoon. / Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. In: Gynecologic Oncology. 2018 ; Vol. 149, No. 2. pp. 381-387.
@article{9626f38e915b4e77be265de889a811cc,
title = "Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer",
abstract = "Objective: Monoclonal antibodies targeting programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) demonstrated promising clinical response. The predictive/prognostic value of PD-1/PD-L1 immunohistochemistry (IHC) has been evaluated in many cancer types. However, the prognostic value of PD-1/PD-L1 IHC has not been evaluated in endometrial cancer. Methods: We conducted a retrospective study to quantify the IHC CD8, PD-1, and PD-L1 expressions in immune cells at center of tumor (CT), invasive margin (IM), and/or tumor cell in 183 primary endometrial cancer samples from a single cohort, followed by their reciprocal combinations, including compartmental differences, and correlated them with overall survival (OS) and progression-free survival (PFS). Results: In repeated Cox multivariable models adjusted by clinicoimmunopathologic factors, high CT-PD-L1 was an independent adverse prognostic factor for PFS in all patients and in the microsatellite-stable subgroup. Immune marker ratios revealed independently shorter PFS for high CT-PD-L1/CT-CD8 and CT-PD-L1/CT-PD-1 ratios. Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-L1 revealed significantly different survival among groups. Conclusions: The high PD-L1/CD8 ratio and the high expression of PD-L1 on immune cells were independent poor prognostic factors for PFS in endometrial cancer, providing insights into the tumor microenvironment.",
author = "Jisup Kim and Sinae Kim and Lee, {Hye Sun} and Wookyeom Yang and Hanbyoul Cho and Chay, {Doo Byung} and Cho, {Seong Jin} and Soonwon Hong and Jae-Hoon Kim",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.ygyno.2018.02.013",
language = "English",
volume = "149",
pages = "381--387",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. / Kim, Jisup; Kim, Sinae; Lee, Hye Sun; Yang, Wookyeom; Cho, Hanbyoul; Chay, Doo Byung; Cho, Seong Jin; Hong, Soonwon; Kim, Jae-Hoon.

In: Gynecologic Oncology, Vol. 149, No. 2, 01.05.2018, p. 381-387.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer

AU - Kim, Jisup

AU - Kim, Sinae

AU - Lee, Hye Sun

AU - Yang, Wookyeom

AU - Cho, Hanbyoul

AU - Chay, Doo Byung

AU - Cho, Seong Jin

AU - Hong, Soonwon

AU - Kim, Jae-Hoon

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Objective: Monoclonal antibodies targeting programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) demonstrated promising clinical response. The predictive/prognostic value of PD-1/PD-L1 immunohistochemistry (IHC) has been evaluated in many cancer types. However, the prognostic value of PD-1/PD-L1 IHC has not been evaluated in endometrial cancer. Methods: We conducted a retrospective study to quantify the IHC CD8, PD-1, and PD-L1 expressions in immune cells at center of tumor (CT), invasive margin (IM), and/or tumor cell in 183 primary endometrial cancer samples from a single cohort, followed by their reciprocal combinations, including compartmental differences, and correlated them with overall survival (OS) and progression-free survival (PFS). Results: In repeated Cox multivariable models adjusted by clinicoimmunopathologic factors, high CT-PD-L1 was an independent adverse prognostic factor for PFS in all patients and in the microsatellite-stable subgroup. Immune marker ratios revealed independently shorter PFS for high CT-PD-L1/CT-CD8 and CT-PD-L1/CT-PD-1 ratios. Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-L1 revealed significantly different survival among groups. Conclusions: The high PD-L1/CD8 ratio and the high expression of PD-L1 on immune cells were independent poor prognostic factors for PFS in endometrial cancer, providing insights into the tumor microenvironment.

AB - Objective: Monoclonal antibodies targeting programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) demonstrated promising clinical response. The predictive/prognostic value of PD-1/PD-L1 immunohistochemistry (IHC) has been evaluated in many cancer types. However, the prognostic value of PD-1/PD-L1 IHC has not been evaluated in endometrial cancer. Methods: We conducted a retrospective study to quantify the IHC CD8, PD-1, and PD-L1 expressions in immune cells at center of tumor (CT), invasive margin (IM), and/or tumor cell in 183 primary endometrial cancer samples from a single cohort, followed by their reciprocal combinations, including compartmental differences, and correlated them with overall survival (OS) and progression-free survival (PFS). Results: In repeated Cox multivariable models adjusted by clinicoimmunopathologic factors, high CT-PD-L1 was an independent adverse prognostic factor for PFS in all patients and in the microsatellite-stable subgroup. Immune marker ratios revealed independently shorter PFS for high CT-PD-L1/CT-CD8 and CT-PD-L1/CT-PD-1 ratios. Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-L1 revealed significantly different survival among groups. Conclusions: The high PD-L1/CD8 ratio and the high expression of PD-L1 on immune cells were independent poor prognostic factors for PFS in endometrial cancer, providing insights into the tumor microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=85044123382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044123382&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2018.02.013

DO - 10.1016/j.ygyno.2018.02.013

M3 - Article

VL - 149

SP - 381

EP - 387

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -